We observed a heterogeneous βAR expression and response to β‐blocker therapy in the tested multiple myeloma patients’ samples, which could potentially be attributed to differences in disease stage, tumor progression, and therapy, as already reported for other cancer types [30, 31]. This evidence concerns the gene ADRB2 and neoplasm.